SBIR (Small Business Innovation Research) and STTR (Small Business Technology Transfer) are two federal funding programs that award grants and contracts to small businesses developing innovative technologies. Together they represent the largest source of early-stage innovation funding in the United States, with participating agencies distributing over $4 billion annually across fields ranging from defense and energy to health and agriculture.
Both programs follow the same basic structure: the government funds small companies to research, develop, and eventually commercialize new technologies that also serve a federal need. The key difference is that STTR requires a formal partnership with a nonprofit research institution like a university, while SBIR does not.
How the Programs Originated
Congress created the SBIR program in 1982 through the Small Business Innovation Development Act, with four goals: stimulate technological innovation, channel small business talent toward federal R&D needs, encourage participation by minority and disadvantaged individuals, and increase private-sector commercialization of federally funded research. A decade later, in 1992, the STTR program was added to bridge the gap between basic science at universities and commercialization at small companies. STTR shares three of SBIR’s four goals but places special emphasis on fostering technology transfer through cooperative R&D between small businesses and research institutions.
SBIR vs. STTR: Key Differences
The scope of work eligible for funding is the same under both programs. The practical differences come down to two things: partnerships and who leads the project.
- Research partnerships. Under SBIR, partnering with a university or research institution is allowed but optional. Under STTR, it is required. The small business must formally team up with a nonprofit research institution such as a university, federally funded R&D center, or nonprofit hospital.
- Principal investigator employment. For SBIR, the lead researcher must be primarily employed (more than 50% of their time) by the small business. For STTR, the lead researcher can be employed by either the small business or the partnering research institution. This flexibility makes STTR appealing when a university professor wants to lead the technical work.
STTR also has a specific budget split requirement. At least 40% of the research budget must go to the small business, and at least 30% must go to the collaborating institution. In both programs, the grant or contract money flows to the small business, which then subcontracts to its partner as needed.
The Three Funding Phases
Both SBIR and STTR use a phased funding model that moves from feasibility testing to full development to commercialization.
Phase I is the proof-of-concept stage. Companies receive funding to explore whether their idea is technically feasible and has commercial potential. At NIH, Phase I awards are capped at roughly $307,000 in total costs. Other agencies set their own limits, but Phase I awards are generally modest and short-term.
Phase II builds on successful Phase I results with more substantial funding for continued R&D. NIH Phase II awards can reach approximately $2 million. Companies use this stage to develop prototypes, refine the technology, and begin planning for the market.
Phase III is the commercialization stage, and it works differently from the first two. Phase III cannot be funded with SBIR or STTR set-aside dollars. Instead, companies pursue commercialization through other government contracts, private investment, or revenue. There is no limit on the number, duration, or dollar value of Phase III awards. Agencies can award Phase III contracts competitively or non-competitively to any company that completed Phase I or Phase II work.
Which Federal Agencies Participate
Federal agencies with large enough extramural R&D budgets are required by law to set aside a percentage of those budgets for SBIR and STTR awards. The two largest participants by far are the Department of Defense, with an SBIR/STTR budget of roughly $2.3 billion, and the Department of Health and Human Services (which includes NIH), at about $1.2 billion. Other significant participants include the Department of Energy ($315 million), NASA ($174 million), and the National Science Foundation ($174 million).
Smaller programs exist at the USDA ($42 million), Department of Homeland Security ($18 million), Department of Commerce ($15 million), Department of Education ($10 million), Department of Transportation ($9 million), and the Environmental Protection Agency ($5 million). Not all agencies run both programs. Some participate in SBIR only, while others offer both SBIR and STTR solicitations. Each agency issues its own topics and has its own review process, so the experience of applying varies significantly depending on where you submit.
Eligibility Requirements
To qualify for either program, a business must meet several criteria. It must be a for-profit company located in the United States with 500 or fewer employees, including affiliates. The company must be more than 50% directly owned and controlled by U.S. citizens or permanent residents. Alternatively, it can be majority-owned by other small businesses that themselves meet the U.S. ownership test.
Eligible business structures include sole proprietorships, partnerships, LLCs, corporations, joint ventures, associations, trusts, and cooperatives. Joint ventures are permitted as long as foreign entities hold less than 50% participation. Companies backed by venture capital, hedge funds, or private equity firms can still qualify for SBIR, provided no single investment firm owns more than 50% of the business.
How Competitive Are These Grants
Competition is stiff and has intensified over time. NIH publishes detailed success rate data for SBIR grants that illustrates the trend. In the early 2000s, about 26 to 30% of Phase I applications were funded. By the 2010s, that rate had dropped into the low to mid-teens. In 2024, only 10% of Phase I applications and 18% of Phase II applications were funded at NIH, for an overall success rate of 12%.
Phase II success rates have historically been higher than Phase I because the applicant pool is smaller and pre-screened (you typically need Phase I results to apply). Even so, Phase II rates at NIH fell from the 40 to 50% range in the early 2000s to the mid-20s in recent years. A “Fast Track” option, which lets companies submit Phase I and Phase II proposals simultaneously, had a 12% success rate in 2024. These numbers are specific to NIH. Other agencies may have different success rates depending on their budget and applicant volume, but the general picture is one of increasing competition across the board.
Intellectual Property Protections
One of the most important features of SBIR and STTR is that the small business retains ownership of any intellectual property it develops. The government receives only a limited, nonexclusive license to use the technology, and it cannot disclose the data to outside parties during the protection period.
The default data rights protection period is now a single, non-extendable 20-year term starting at the date of contract award. This replaced an earlier system that offered an extendable five-year period. Once the 20 years expire, the government receives perpetual “government purpose rights,” meaning it can use and share the data for government purposes but not for commercial use. This structure is designed to give small businesses a long runway to commercialize their technology without competing against their own government-funded inventions.
What Makes These Programs Unusual
SBIR and STTR occupy a unique space in the funding landscape. Unlike venture capital, they require no equity. Unlike traditional government contracts, they are specifically reserved for small companies. And unlike most grants, they are explicitly designed to produce commercial products, not just research papers. For small technology companies, particularly those working in areas with long development timelines like medical devices, clean energy, or defense systems, these programs can provide critical non-dilutive funding during the years between a promising idea and a viable product.